Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer.
暂无分享,去创建一个
M. Nucci | P. Bacha | N. Spector | C. Solza | W. Pulcheri | A. Bueno | T. Perecmanis
[1] J. Romero-Vivas,et al. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] M. Nucci,et al. The treatment of acute myeloid leukemia in Brazil: progress and obstacles. , 1995, Haematologica.
[3] M. Nucci,et al. Quinolone prophylaxis in neutropenic patients - efficacy versus resistance. , 1994, Oncology reports.
[4] H. Richet,et al. Fluoroquinolone use and fluoroquinolone resistance: is there an association? , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] M. Nucci,et al. Ceftazidime and amikacin as empirical treatment of febrile episodes in neutropenic patients. , 1994, The Journal of infection.
[6] T. Calandra,et al. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. , 1994, The New England journal of medicine.
[7] G. Bodey. Empirical antibiotic therapy for fever in neutropenic patients. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] P. Pizzo,et al. Management of fever in patients with cancer and treatment-induced neutropenia. , 1993, The New England journal of medicine.
[9] G. Bodey,et al. Infectious complications of indwelling vascular catheters. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] E. Anaissie,et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. , 1992, Archives of internal medicine.
[11] Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. , 1991, Annals of internal medicine.
[12] R. Woolson,et al. Risk factors for hospital-acquired candidemia. A matched case-control study. , 1989, Archives of internal medicine.
[13] I. Dybedal,et al. Respiratory insufficiency in acute leukemia following treatment with cytosine arabinoside and septicemia with streptococcus viridans. , 1989, European journal of haematology.
[14] R. Wenzel,et al. The mortality of hospital-acquired bloodstream infections: need for a new vital statistic? , 1988, International journal of epidemiology.
[15] W. Schaffner,et al. Frequency of broviac catheter infections in pediatric oncology patients. , 1986, The Journal of infectious diseases.
[16] L. Elting,et al. Aztreonam therapy in neutropenic patients with cancer. , 1986, The American journal of medicine.
[17] J. Mcgowan,et al. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. , 1983, Reviews of infectious diseases.
[18] C. Schiffer,et al. Improved prognosis for granulocytopenic patients with gram-negative bacteremia. , 1980, The American journal of medicine.
[19] P. Pizzo,et al. Treatment of gram‐positive septicemia in cancer patients , 1980, Cancer.
[20] R. Feld,et al. β-Lactum antibiotics alone or in combination with gentamicin for therapy of gram-negative bacillary infections in neutropenic patients , 1976, The American journal of the medical sciences.